Paper Details

  1. Home
  2. Paper Details

Double blind cross-over clinical trial of acebutolol and propranolol in angina pectoris.

Author: PandhiP, SethiV, SharmaB K, SharmaP L, WahiP L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Acebutolol (100-400 mg) and propranolol (40-160 mg) three times a day effectively reduced anginal attacks, nitroglycerine tablet consumption, and increased exercise tolerance in 24 patients. Both drugs had mild side effects.
Paper Details　
Original Abstract of the Article :
Twenty-four patients with classical angina of effort completed this double-blind cross-over clinical trial of acebutolol and propranolol. Both acebutolol (100-400 mg) and propranolol (40-160 mg) three times a day produced a significant reduction in the incidence of anginal attacks, consumption of ni...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3908331

データ提供：米国国立医学図書館（NLM）

Acebutolol vs. Propranolol for Angina Pectoris: A Double-Blind Crossover Trial

This double-blind crossover trial, conducted in the vast desert of cardiovascular research, compares the efficacy of two beta-blockers, acebutolol and propranolol, in treating angina pectoris. The authors carefully analyze the effects of both drugs on anginal attack frequency, nitroglycerin consumption, and exercise tolerance. Their findings demonstrate that both acebutolol and propranolol significantly reduce anginal symptoms, but emphasize the need for individualized dosing of acebutolol to optimize treatment effects.

Individualized Dosing: Tailoring Treatment for Angina Pectoris

The research underscores the importance of individualized dosing when treating angina pectoris. The authors found that while both acebutolol and propranolol were effective in reducing anginal symptoms, the optimal dose of acebutolol varied significantly among patients. Think of it like navigating a sandstorm – the right approach for one traveler may not be ideal for another. This study highlights the need for a personalized approach to medication management for angina pectoris.

Navigating the Desert of Cardiovascular Health: A Personalized Approach

As a researcher, I am constantly reminded of the importance of personalized medicine in healthcare. This research reinforces this concept, emphasizing the need for individualized dosing strategies in treating angina pectoris. It's like finding the right path through a desert – what works for one person may not work for another. This study emphasizes the importance of tailoring treatment to the unique needs of each individual patient.

Dr.Camel's Conclusion

This study compares the efficacy of acebutolol and propranolol in treating angina pectoris. The findings highlight the importance of individualized dosing for acebutolol, emphasizing the need for a personalized approach to medication management for angina pectoris. It's like finding the right oasis in a vast and unforgiving desert – a personalized approach to healthcare is essential for success.
Date :
  1. Date Completed 1986-02-12
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3908331

DOI: Digital Object Identifier

3908331

Related Literature

Article Analysis
・Side Effects of acebutolol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.